South Africa's First National Bank (FNB) has launched a 'Crypto Investing' feature allowing nearly 9 million retail clients to buy, sell, and trade five cryptocurrencies directly within its existing share-trading platform. Supported assets include Bitcoin, Ethereum, XRP, Solana, and USDT, with trades starting as low as R10 (~$0.60). The service operates 24/7 and funds are drawn directly from clients' FNB accounts, but crypto assets cannot be transferred outside the bank due to regulatory and security reasons. This move reflects growing demand for crypto investments in South Africa and positions FNB as a trusted gateway, with plans to expand asset offerings and provide educational resources.
South Africa's First National Bank has enabled nearly 9 million clients to trade cryptocurrencies within its platform. For readers following the broader crypto market, here is Pluang's snapshot as of Oct 07, 2026 02:32 WIB: out of 50 major cryptocurrencies, 14 rose and 35 fell today. Notable movers include THETA with a 3.09% gain and 100% sell order activity, CRV down 2.64% with a near-even buy-sell split, and ALGO down 2.64% but with 73% buy order activity.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
